BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) reported additional positive data from a second interim analysis of its Phase 2 APeX-1 clinical trial sending the stock price soaring $1.60 to close at $6.73.
BioCryst Pharmaceuticals reports additional data
May 25, 2017 at 17:21 PM EDT
